What is the recommended dosing of Zofran (ondansetron) for treating nausea, and what are its contraindications, side effects, and alternative anti‑emetics?

Ondansetron (Zofran) Dosing and Clinical Use for Nausea

For adults with nausea, ondansetron 8 mg orally or IV is the standard initial dose, with the specific regimen depending on the underlying cause—chemotherapy-induced nausea requires scheduled dosing (8 mg twice daily), while postoperative or general nausea typically responds to single-dose or as-needed administration.

Standard Dosing by Clinical Context

Chemotherapy-Induced Nausea and Vomiting

High emetogenic risk (cisplatin ≥50 mg/m² or anthracycline + cyclophosphamide):

• Day 1: 8 mg oral twice daily OR 8 mg (or 0.15 mg/kg) IV once, given 30 minutes before chemotherapy 1, 2
• Days 2-4: 8 mg oral twice daily (every 12 hours) 1
• Combine with dexamethasone and NK₁ receptor antagonist for optimal control 1

Moderate emetogenic risk:

• Day 1: 8 mg oral twice daily OR 8 mg IV, starting 30 minutes pre-chemotherapy 1, 2
• Days 2-3: 8 mg oral twice daily 1
• Combine with dexamethasone 8 mg 1

Low emetogenic risk:

• 8 mg oral twice daily on day of chemotherapy only 1
• May use with or without dexamethasone 1

Postoperative Nausea and Vomiting

Prophylaxis:

• 16 mg oral (two 8 mg tablets) given 1 hour before anesthesia induction 2
• Alternatively: 4 mg IV at induction or 30 minutes before end of surgery 3, 4
• Clinical pearl: Late administration (within 30 minutes of surgery completion) is significantly more effective for preventing delayed PONV than pre-induction dosing 4

Treatment (established PONV):

• 4 mg IV as single dose 3
• Superior to metoclopramide 10 mg for patient satisfaction and nausea control at 24 hours 3

Radiation-Induced Nausea

Total body irradiation or abdominal radiation:

• 8 mg oral three times daily 2
• First dose 1-2 hours before radiation
• Continue every 8 hours for 1-2 days after completion 2

General/Undifferentiated Nausea

Prehospital/Emergency setting:

• 4 mg IV, IM, or oral dissolving tablet 5
• Mean nausea reduction of 4.0 points on 10-point scale 5
• IV route most effective, followed by IM, then oral 5

Pediatric Dosing

Ages 4-11 years (moderate emetogenic chemotherapy):

• 4 mg oral three times daily on day 1 (at 0,4, and 8 hours after first dose) 2
• Continue 4 mg every 8 hours for 1-2 days post-chemotherapy 2

Ages ≥12 years:

• Use adult dosing 2

Ages ≥6 months (acute FPIES):

• 0.15 mg/kg IM (maximum 16 mg) for moderate-to-severe episodes 6
• Weak recommendation due to limited evidence, but promising for stopping emesis 6

Special Populations

Severe Hepatic Impairment (Child-Pugh ≥10)

• Maximum 8 mg total daily dose 2
• Clearance reduced 2-3 fold with half-life increased to 20 hours 2

Renal Impairment

• No dose adjustment needed, even with severe impairment (CrCl <30 mL/min) 2

Elderly

• No routine dose adjustment required 2
• Half-life increases to mean 7.9 hours (vs 3.5 hours in younger adults) 7

Important Contraindications and Warnings

Absolute contraindication:

• Concomitant use with apomorphine (risk of profound hypotension and loss of consciousness) 2

QT prolongation risk:

• Use caution in patients with cardiac disease, especially children 6
• Avoid doses >16 mg IV (associated with increased QT prolongation) 2
• Monitor ECG in high-risk patients

Serotonin syndrome:

• Risk when combined with other serotonergic drugs (SSRIs, SNRIs, MAOIs, triptans)
• Monitor for agitation, hallucinations, tachycardia, hyperthermia

Common Side Effects

Most frequent (chemotherapy patients):

• Headache (9-27%)
• Constipation (6-11%)
• Diarrhea (2-7%)
• Transient liver enzyme elevations 8

Postoperative patients:

• Wound problems, anxiety, headache, drowsiness, pyrexia 9
• Overall incidence of adverse events is low across all indications 10

Alternative Antiemetics

When ondansetron fails or is contraindicated:

1. Metoclopramide 10-20 mg oral/IV every 6-8 hours

   • Less effective than ondansetron for chemotherapy-induced nausea 9, 8
   • Dopamine antagonist; risk of extrapyramidal symptoms

2. Prochlorperazine 5-10 mg oral/IV every 6-8 hours

   • Reasonable alternative for low emetogenic risk 1
   • More sedating than ondansetron

3. Dexamethasone 8-20 mg oral/IV

   • Essential component of combination therapy for moderate-high risk chemotherapy 1
   • Can be used alone for low-risk situations

4. Aprepitant/fosaprepitant (NK₁ antagonists)

   • Reserved for high emetogenic chemotherapy in combination regimens 1
   • Aprepitant: 125 mg day 1, then 80 mg days 2-3 1

5. Olanzapine 10 mg oral daily

   • Increasingly used for breakthrough or refractory chemotherapy-induced nausea 1
   • Highly effective but causes sedation

6. Granisetron (alternative 5-HT₃ antagonist)

   • 1-2 mg oral or 1 mg IV 1
   • Similar efficacy to ondansetron; may use if ondansetron unavailable

Clinical Pearls

• Combination therapy is superior: Ondansetron + dexamethasone significantly outperforms either agent alone for chemotherapy-induced nausea 1, 9
• Route matters for speed: IV administration provides fastest relief (mean improvement 4.4 points), followed by IM (3.6 points), then oral (3.3 points) 5
• Cost consideration: Ondansetron is significantly more expensive than metoclopramide; reserve for patients at high risk for metoclopramide side effects or when metoclopramide fails 8
• Pregnancy safety: Limited data (176 exposures) shows no increased malformation risk above baseline (3.6% major malformations) 11, though not FDA-approved for this indication
• Not effective for motion sickness: High-dose ondansetron does not prevent motion sickness in susceptible individuals 12